Pharmaceutical & Medication-Related Cases

The pharmaceutical landscape is evolving rapidly, particularly with the rise of “Low-T” clinics and new weight-loss medications like Ozempic and Wegovy. Dr. Philip Levin provides essential physician expert testimony in cases where the improper management of these therapies has led to serious injury. As a testosterone and obesity expert witness, he evaluates whether clinics followed the standard of care and performed necessary baseline testing before starting therapy. Attorneys across the Baltimore-Washington region trust his professional analysis to determine if a provider prioritized marketing and speed over patient safety and clinical integrity.

Testosterone litigation often involves preventable cardiovascular events, such as heart attacks or strokes caused by polycythemia (thickened blood). Dr. Levin explains to a jury how excess testosterone impacts the circulatory system and why a physician’s failure to monitor a patient’s hematocrit levels constitutes a breach of duty. Similarly, obesity-related litigation often centers on the mismanagement of metabolic status or the failure to monitor side effects of new GLP-1 agonists. Dr. Levin provides legal teams with a focused analysis of the physiological impacts of these treatments, ensuring that the “clinical truth” is understood in cases where patients suffered severe metabolic imbalances or neurological damage.

In his role as a pharmaceutical expert witness, Dr. Levin also investigates “Failure to Warn” cases and adverse drug reactions involving a wide range of endocrine-active medications. He provides a professional review of clinical trials and FDA-approved labeling to determine if a physician deviated from the standard of care. His deep roots in regional medicine allow him to provide a perspective that is both technically authoritative and locally relevant to cases in Maryland, Virginia, and beyond. He assists attorneys in untangling the complex web of drug interactions, helping them secure justice for those harmed by pharmaceutical negligence and a lack of proper clinical oversight.